Navigation Links
Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients
Date:8/5/2009

SAN DIEGO, Aug. 5 /PRNewswire/ -- Ceregene, Inc. today announced that the Michael J. Fox Foundation will provide partial funds for long-term follow-up testing of patients enrolled in the company's Phase 2 trial of CERE-120 for Parkinson's disease. The funding will enable Ceregene to collect and analyze more extensive data for up to 48 months from patients with advanced Parkinson's disease who were enrolled in the double-blind, controlled trial which ended in November 2008.

As was previously announced, the Phase 2 trial of CERE-120 involving 52 patients, failed to demonstrate a difference in the primary endpoint between patients in the CERE-120 versus control group. It was subsequently announced, however, that CERE-120 suggested improvement on several secondary endpoints at 12 months, and at 18 months, a statistically significant treatment effect on the primary endpoint emerged, while several additional secondary endpoints also showed improvement. In contrast, on no measure did sham patients perform better than CERE-120 patients, at either 12 or 18 months. Based on those findings, and insight gained from analyses of post-mortem brain tissue from two CERE-120 treated patients, the company has revised the dosing regimen and expects to initiate a new trial of CERE-120 in the near future.

"We are pleased to be able to gather unique, long-term data from both CERE-120 treated and control patients and thus gain more information about the potential long-term effects of CERE-120 on Parkinson's disease," stated Raymond T. Bartus, Ph.D., Ceregene's executive vice president and chief scientific officer. "We very much appreciate the support the MJFF has provided to enable us to expand the testing of these patients and further enrich our data base. Our conviction about CERE-120's potential to treat Parkinson's disease remains strong. We learned a significant amount from the initial Phase 2 trial wh
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinsons Disease
2. Ceregene Announces Two Key Additions to Leadership Team
3. Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer
4. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
5. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
6. Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab
7. Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia
8. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
9. SyntheMed Receives US Patent on Novel Polymer Technology
10. Sunesis Receives Approval for Listing on The NASDAQ Capital Market
11. Anesiva Receives NASDAQ Delisting Staff Determination Letter

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...RNewswire-FirstCall/-YMBioSciencesInc.(NYSEAmex: Y...thatidentifiesandadvancesadiverseportfolioofpromis...ent,todayreportedthatCytopia(ASX:CYT)hascommencede...,orally-administeredJAK1/JAK2inhibitor.Thetrialisb...oposaltomergeCytopiaintoYMhasbeenpreviouslyannounc...
(Date:11/23/2009)...swire/-InimexPharmaceuticals,Inc.announcedtodaytha...ndCEO. ,, Abramsbringsmorethan25yearsofdrugdisc...ntorofthenuclearmedicineimagingagent,Cardiolite,an...sManager,BiomedicalResearchWorldwide.In1996,Abrams...identandCEOfrom1996to2006.AnorMEDdiscoveredanddeve...
(Date:11/20/2009)... , , , , , , , ... A team of scientists from Washington University...ing Harbor Laboratory and Iowa State University ha... , Click here for more information. ... , , , , , , , ...
(Date:11/20/2009)...v. 20 Novavax, Inc. (Nas... underwritten public offering of 6,800,000 shares ....30 per share. The approximately $21 million of n...ounts and commissions, will be used for preclinica...cines, internal research and development programs,...
Breaking Biology Technology:YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4Inimex Announces Appointment of New CEO 2Amaizing: Corn genome decoded 2Amaizing: Corn genome decoded 3Amaizing: Corn genome decoded 4Novavax Prices Public Offering of Common Stock 2
...ved for Marketing in the United States, Trade Name... TOKYO and INDIANAPOLIS, Jan. 4 Daiichi Sankyo,C...any (NYSE: LLY ) today,announced that on Wednesda...ation (NDA) for prasugrel to the U.S. Food and Dru...latelet agent, initially in development,for the tr...
... Calif., Jan. 4 Thermage, Inc.,(Nasdaq: THRM ), ...aesthetic,industry, announced today that it will p... Conference at The Palace Hotel in New York City. ..., January 11, 2008 at 11:00,a.m. Eastern Time. Ste...cutive Officer, will review the Company,s business...
...ORK (Oct. 31, 2007) -- In the face of terrorism an...trauma systems that improve survival for criticall...Yet many fundamental assumptions underlying these ...e to send the sickest patients to the hospital fir...tific scrutiny. Now, for the first time, researche...
Other Biology Technology:Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration 2Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration 3Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration 4Triage study challenges notions of emergency medical response to disaster 2Triage study challenges notions of emergency medical response to disaster 3Triage study challenges notions of emergency medical response to disaster 4
(Date:11/23/2009)... release is available in German . , Of all ...cumulate in the atmosphere where it contributes to...ceans and terrestrial ecosystems such as forests, ...service" of aquatic and terrestrial ecosystems is ...ways of reducing climate change. However, new gree...
(Date:11/22/2009)...sus of Marine Life scientists have inventoried an ...of deep sea species that have never known sunlight...gid black world down to 5,000 meters (~3 miles) be...cameras, sonar and other vanguard technologies, an...s now number 17,650, a diverse collection of speci...
(Date:11/22/2009)...bridge, MA November 23, 2009 Agios Pharmaceutica...ished, for the first time, that the mutated IDH1 g...cancer-causing gene, or oncogene. This breakthroug...oduces a metabolite, 2-hydroxyglutarate (2HG), whi...rogression of gliomas, the most common type of bra...
Breaking Biology News(10 mins):Intensive land management leaves Europe without carbon sinks 2Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 2Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 3Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 4Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 5Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 6Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 7Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 8Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 9Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 2Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 3Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 4Gain Entry to the Closed 2009 Chicago Marathon by Joining Susan G Komens Marathon for the Cure 28R 29 48393 1Gain Entry to the Closed 2009 Chicago Marathon by Joining Susan G Komens Marathon for the Cure 28R 29 48393 2New Analysis Shows Efficacy of SIMPONI 28TM 29 28golimumab 29 in Anti TNF Experienced Rheumatoid Arthritis Patients 4579 1New Analysis Shows Efficacy of SIMPONI 28TM 29 28golimumab 29 in Anti TNF Experienced Rheumatoid Arthritis Patients 4579 2New Analysis Shows Efficacy of SIMPONI 28TM 29 28golimumab 29 in Anti TNF Experienced Rheumatoid Arthritis Patients 4579 3New Analysis Shows Efficacy of SIMPONI 28TM 29 28golimumab 29 in Anti TNF Experienced Rheumatoid Arthritis Patients 4579 4New Analysis Shows Efficacy of SIMPONI 28TM 29 28golimumab 29 in Anti TNF Experienced Rheumatoid Arthritis Patients 4579 5New Analysis Shows Efficacy of SIMPONI 28TM 29 28golimumab 29 in Anti TNF Experienced Rheumatoid Arthritis Patients 4579 6New Analysis Shows Efficacy of SIMPONI 28TM 29 28golimumab 29 in Anti TNF Experienced Rheumatoid Arthritis Patients 4579 7New Analysis Shows Efficacy of SIMPONI 28TM 29 28golimumab 29 in Anti TNF Experienced Rheumatoid Arthritis Patients 4579 8New Analysis Shows Efficacy of SIMPONI 28TM 29 28golimumab 29 in Anti TNF Experienced Rheumatoid Arthritis Patients 4579 9New Analysis Shows Efficacy of SIMPONI 28TM 29 28golimumab 29 in Anti TNF Experienced Rheumatoid Arthritis Patients 4579 10Landmark Study Published in New England Journal of Medicine 48389 1Landmark Study Published in New England Journal of Medicine 48389 2Landmark Study Published in New England Journal of Medicine 48389 3
...DA, Md. (July 1, 2008) Recipe to recover more quic...wash down with five or six cups of strong coffee. ...ng exercise, is replenished more rapidly when athl...ng exhaustive exercise, new research from the onli...shows. Athletes who ingested caffeine with carbohy...
...ogy of penguins makes these iconic swimming and di... susceptible to environmental changes. Pronounced ...shing, mining, and oil and gas development at lowe...according to P. Dee Boersma, of the University of ...ue of BioScience, Boersma provides a first-perso...
... July 1, 2008 The current standard practice of gi...event brain damage caused by oxygen deprivation ma... UT Southwestern Medical Center have found. , Bra...ypoxic-ischemic brain injury, is one of the most c...amage among infants and children. This can happen ...
Other Biology News:Post-exercise caffeine helps muscles refuel 2Post-exercise caffeine helps muscles refuel 3Post-exercise caffeine helps muscles refuel 4Resuscitation technique after brain injury may do more harm than good 2
...nd scales with RS232 ports and sends that data tra... the weight into the program, BalanceTalk can auto...rser extracts required data , Add date/time stamps...timed intervals , Keyboard macros automate cursor ...
Rabbit Anti-Human Prolactin Releasing Hormone Receptor (GPR10) Polyclonal Antibody, Unconjugated from IMGENEX
...ection and automation that is controlled from with...cel , Pre-configured library of interfaces for ba...es can be added and configured by the user , Col...eet , Allows for multi-tasking during data colle...
ReBlot™ Plus Strong Antibody Stripping Solution, 10x from Upstate
Biology Products: